Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects

Journal of Clinical Pharmacology

Volumn 48, Issue 1, 2008, Pages 73-84

  Ping Liu, ^a   Foster, Grover ^a   Labadie, Robert R ^a   Gutierrez, Maria J ^b   Sharma, Amarnath ^a  

^a PFIZER INC   (United States)

^b Univ S Carolina Sch Med Vice P   (United States)

Author keywords

Efavirenz; Pharmacokinetic; Voriconazole

Indexed keywords

BICARBONATE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; EFAVIRENZ; PLACEBO; VORICONAZOLE;

ABNORMAL VISION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MYOPATHY; NORMAL HUMAN; PHOTOPHOBIA; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; STEADY STATE;

ADOLESCENT; ADULT; AGE FACTORS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BENZOXAZINES; BODY WEIGHT; CAPSULES; CREATINE KINASE; DRUG INTERACTIONS; HEART BLOCK; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RHABDOMYOLYSIS; TABLETS; TRIAZOLES;

EID: 37349046483     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007309703     Document Type: Article

References (27)

1. Cuenca-Estrella M., Rodriguez-Tudela JL, Mellado E., Martinez-Suarez JV, Monzon A. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother. 1998 ; 42: 531-533.
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 1998 ; 36: 198-202.
3. Pfaller MA, Zhang J., Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother. 1999 ; 43: 169-171.
4. Hoffman HL, Rathbun RC Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs. 2002 ; 11: 409-429.
5. Purkins L., Wood N., Ghahramani P., Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol. 2003 ; 56 (suppl 1). 37-44.
6. Purkins L., Wood N., Kleinermans D., Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol. 2003 ; 56 (suppl 1). 24-29.
7. Wood N., Tan K., Purkins L., et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol. 2003 ; 56 (suppl 1). 56-61.
8. Hyland R., Jones BC, Smith DA Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003 ; 31: 540-547.
9. Ikeda Y., Umemura K., Kondo K., Sekiguchi K., Miyoshi S., Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther. 2004 ; 75: 587-588.
10. Luo HR, Poland RE, Lin KM, Wan YJ Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther. 2006 ; 80: 33-40.
11. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999 ; 9: 539-549.
12. SUSTIVA (Efavirenz) [package insert]. Princeton, NJ: Bristol-Myers Squibb ; 2006.
13. von Moltke LL, Greenblatt DJ, Granda BW, et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 ; 41: 85-91.
14. Hariparsad N., Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004 ; 44: 1273-1281.
15. Mouly S., Lown KS, Kornhauser D., et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther. 2002 ; 72: 1-9.
16. Falloon J., Piscitelli S., Vogel S., et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis. 2000 ; 30: 313-318.
17. Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther. 2002 ; 71: 57-67.
18. Clarke SM, Mulcahy FM, Tjia J., et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001 ; 51: 213-217.
19. Liu P., Foster G., LaBadie R., Gutierrez M., Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy subjects [abstract]. Clin Pharmacol Ther. 2005 ; 77: 40.
20. VFEND (Voriconazole) [package insert]. New York: Pfizer, Inc ; 2006.
21. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl. 1997 ; 691: 441-448.
22. Langmann P., Schirmer D., Vath T., Zilly M., Klinker H. High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy. J Chromatogr B Biomed Sci Appl. 2001 ; 755: 151-156.
23. Saras-Nacenta M., Lopez-Pua Y., Lipez-Cortes LF, Mallolas J., Gatell JM, Carne X. Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2001 ; 763: 53-59.
24. Kupper L., Hafner K. How appropriate are popular sample size formulas? Am Stat. 1989 ; 43: 101-105.
25. Barry M., Feely J. Enzyme induction and inhibition. Pharmacol Ther. 1990 ; 48: 71-94.
26. Ohnhaus EE, Breckenridge AM, Park BK Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol. 1989 ; 36: 39-46.
27. Park BK, Breckenridge AM Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet. 1981 ; 6: 1-24.